NY-CURIA
22.12.2021 15:02:05 CET | Business Wire | Press release
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA (mRNA) solution, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle (LNP) formulation and development for full-scale sterile fill-finish services.
Curia’s mRNA solution is designed to streamline the development and delivery of mRNA-based products, which span various therapeutic areas including cancer, heart disease and chronic illnesses in addition to its current application in vaccines.
“The extraordinary impact of mRNA on the COVID-19 pandemic demonstrates its potential to save and improve lives,” said Curia Chairman and Chief Executive Officer John Ratliff. “mRNA has the potential to play a pivotal role in the next frontier of treatments for unmet medical needs. Curia’s capabilities enable customers to accelerate the discovery and development of next-generation mRNA therapeutics from curiosity to cure.”
Curia’s team brings a powerful combination of proven expertise, speed and reliability across research, process development and manufacturing to accelerate mRNA product development timelines:
Discovery
Curia’s mRNA solution combines expertise and a proven track record of success in key scientific disciplines including molecular biology, protein production and analysis, enzymes, nucleosides and lipids. The platform’s ability to provide high-quality constructs through in-house research and analysis capabilities enables accelerated timelines for delivery.
Development of Lipid and RNA Drug Substance Through Manufacturing
Curia’s end-to-end capabilities extend from production of plasmid DNA and manufacturing of enzymes and nucleosides at gram-to-kilogram scale, to drug substance development through first-in-human clinical supply manufacturing. Its five sites in California and Massachusetts provide reliable plasmid production for “traditional” and self-amplifying mRNA drug substance. First-in-human clinical-scale cGMP manufacturing is supplemented by in-house analytical capabilities for product testing and release.
Curia has a proven track record in the rapid development of numerous specialized lipids for mRNA applications and the ability to manufacture lipids to metric-ton scale in accordance with cGMP. Curia’s scientists have expertise in coupling synthesis with highly effective separations and purifications of APIs and functional excipients.
Development of Lipid Nanoparticle Formulation, Testing and Sterile Fill-Finish Through Manufacturing
Curia’s mRNA solution includes complex formulation capabilities and experience in liposome and lipid nanoparticles led by its expert scientists. Curia completes its end-to-end offering with clinical and commercial aseptic sterile fill-finish capability and capacity. Its facilities provide process development and first-in-human clinical manufacturing through to full commercial manufacturing of mRNA injectable dosage products in accordance with cGMP.
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,700 employees at 29 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OKX Card Usage Surges Across Europe as Crypto Moves Into Everyday Spending19.8.2026 09:30:00 CEST | Press release
OKX Card purchase volume rises 280% year over year as European customers increasingly use digital assets for groceries, transport and other everyday expenses OKX, a leading global fintech company and crypto trading platform, today announced significant growth in everyday use of the OKX Card across Europe, with purchase volume increasing 280% year over year this summer and transactions rising 178%, as customers increasingly use the Card for routine spending including groceries, transport and fuel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819423550/en/ The OKX Card is designed to bridge the gap between holding digital assets and using them in everyday life, bringing earning, spending, and rewards together within the broader OKX ecosystem. The growth comes as crypto cards gain momentum across the wider payments industry. Industry-wide crypto card purchase volume reached a record $759 million in July, signalling that di
SAP strengthens its cloud infrastructure in Germany with BSI-approved Layer 1 encryption from Adva Network Security19.8.2026 09:00:00 CEST | Press release
News summary: SAP needed to secure connectivity between its German data centers to meet strict confidentiality, compliance and data control requirements BSI-approved Layer 1 encryption from Adva Network Security enables SAP to protect all data streams and future-proof its infrastructure against quantum threats Solution strengthens sovereign cloud foundations for government, critical infrastructure and regulated industries with high security and compliance needs Adva Network Security, an Adtran company, today announced that SAP is harnessing its Layer 1 encryption technology to secure connectivity between its data centers in Walldorf and St. Leon-Rot, Germany. The solution secures data directly at the optical transmission layer and is approved by the Federal Office for Information Security (BSI) for information classified up to “Verschlusssache – Nur für den Dienstgebrauch” (VS-NfD) – “For Official Use Only.” By strengthening the protection of data in transit, SAP is enhancing the secur
Qatar to Showcase Its Gaming Ambitions at Gamescom 202619.8.2026 09:00:00 CEST | Press release
Invest Qatar, the country’s Investment Promotion Agency, and Media City Qatar will participate at Gamescom 2026 through the “Qatar Pavilion”, highlighting Qatar’s growing role as a regional hub for game development, digital content and esports. Held annually in Cologne, Germany, Gamescom, a leading global event, brings together developers, publishers, investors and creators. Qatar’s participation reflects its focus on building a competitive, innovation-led ecosystem for gaming and interactive media. Mohammed Al Mulla, Head of Investment Development, Invest Qatar, said: “Gamescom provides a key platform to connect with global gaming leaders and highlight emerging opportunities across Qatar and the wider Middle East. We are focused on enabling companies to enter and scale in a high-growth market through a business environment designed for innovation and long-term success.” Dr. Fahad Abdulla Al Hajri, Business Development Manager, Media City Qatar, said: "Gaming is becoming one of the def
IFF to Webcast Fireside Chat at Barclays Global Consumer Conference on Sept. 1018.8.2026 22:15:00 CEST | Press release
IFF (NYSE: IFF) today announced that Chief Executive Officer Erik Fyrwald will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, Sept. 10, 2026 at 945 a.m. ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818490253/en/
Lehman Brothers Treasury Announces the Successful Sale of its Remaining Intercompany Claim against Lehman Brothers Holdings Inc.18.8.2026 21:15:00 CEST | Press release
In connection with its previously announced final wind-down, Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”), through its U.S. counsel Herbert Smith Freehills Kramer (US) LLP, announced that its placement agent, Seaport Loan Products LLC, successfully closed the sale of LBT’s remaining $19.6 billion Class 4A intercompany claim against Lehman Brothers Holdings Inc. The net proceeds of the sale, together with certain available cash (but after deducting various sale-related and other administrative costs and expenses), will be used to fund a final distribution to the holders of LBT’s existing notes, after which such existing notes will be canceled and LBT shall be fully wound down. As a result, LBT will cease to exist. LBT expects the final distribution to occur in the course of October 2026 and the wind down to have been completed before the end of 2026. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818004215/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom